Free Trial

ADMA Biologics (ADMA) Stock Price, News & Analysis

+0.06 (+0.62%)
(As of 11:16 AM ET)
Today's Range
50-Day Range
52-Week Range
565,702 shs
Average Volume
2.73 million shs
Market Capitalization
$2.21 billion
P/E Ratio
Dividend Yield
Price Target

ADMA Biologics MarketRank™ Stock Analysis

Analyst Rating
3.25 Rating Score
7.9% Upside
$10.50 Price Target
Short Interest
3.82% of Shares Sold Short
Dividend Strength
News Sentiment
0.59mentions of ADMA Biologics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$3.93 M Sold Last Quarter
Proj. Earnings Growth
From $0.35 to $0.52 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

630th out of 920 stocks

Biological Products, Except Diagnostic Industry

97th out of 154 stocks

ADMA stock logo

About ADMA Biologics Stock (NASDAQ:ADMA)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Stock Price History

ADMA Stock News Headlines

Giving ADMA Biologics A Well-Deserved 'Booyah'
ADMA Biologics, Inc.
Adma Biologics: Q1 Earnings Snapshot
3 'Buy-Rated' Biotech Stocks Under $10
ADMA Biologics Inc
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
ADMA Apr 2024 5.000 put
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$258.21 million
Cash Flow
$0.05 per share
Book Value
$0.67 per share


Free Float
Market Cap
$2.20 billion
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Adam S. GrossmanMr. Adam S. Grossman (Age 47)
    Co-Founder, President, CEO, Interim CFO & Director
    Comp: $1.59M
  • Dr. Jerrold B. Grossman D.P.S. (Age 76)
    Ph.D., Co-Founder & Vice Chairman of the Board
    Comp: $90k
  • Ms. Kaitlin Kestenberg (Age 37)
    COO & Senior VP of Compliance
  • Mr. Drew Pantello
    Vice President of Marketing & Corporate Development
  • Ms. Cindy Petersen
    Executive Director of Human Resources
  • Mr. Skyler Bloom
    Senior Director of Business Development & Corporate Strategy
  • Mr. Brad Tade
    Vice President of Financial Operations

ADMA Stock Analysis - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings
or view top-rated stocks.

What is ADMA Biologics' stock price target for 2024?

4 brokers have issued 12 month price targets for ADMA Biologics' stock. Their ADMA share price targets range from $10.00 to $12.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 7.9% from the stock's current price.
View analysts price targets for ADMA
or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2024?

ADMA Biologics' stock was trading at $4.52 at the beginning of the year. Since then, ADMA shares have increased by 115.3% and is now trading at $9.73.
View the best growth stocks for 2024 here

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ADMA earnings forecast

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.03. The biotechnology company earned $81.90 million during the quarter, compared to analysts' expectations of $77.28 million. ADMA Biologics had a positive trailing twelve-month return on equity of 17.24% and a negative net margin of 1.29%. The business's revenue for the quarter was up 43.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.03) earnings per share.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics issued an update on its FY 2025 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410.0 million-, compared to the consensus revenue estimate of $389.9 million.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.56%), AWM Investment Company Inc. (2.50%), Magnetar Financial LLC (2.04%), Assenagon Asset Management S.A. (1.47%), Mesirow Institutional Investment Management Inc. (1.14%) and Rice Hall James & Associates LLC (0.53%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon.
View institutional ownership trends

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADMA) was last updated on 5/23/2024 by Staff

From Our Partners